Fostex

Quick links to important sections

Fostex

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fostex

Quick Facts Description
Active Ingredients Beclometasone dipropionate, Formoterol fumarate dihydrate
Form Pressurized metered-dose inhaler (pMDI), Inhalation aerosol
Pharmacological Class Inhaled Corticosteroid / Long-acting Beta2-Agonist Combination (ICS/LABA)
Common Use Management of chronic obstructive airway diseases (Prescription-Only)
Origin Synthetic

What Type of Medication is Fostex?

Fostex (also known internationally by the trade names Fostair/Innovair) is a fixed-dose combination (FDC) medicine administered via the inhalation route, defined pharmacologically as a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA). This synthetic medicine is delivered through a pressurized metered-dose inhaler (pMDI), which produces an inhalation aerosol designed to deposit the active substances directly into the respiratory tract. This combination is a widely authorized therapy for respiratory inhalation, maximizing local effect and minimizing systemic exposure. This design is clinically recognized for maximizing therapeutic action at the target site. This FDC approach is a distinguishing feature, contrasting with the separate administration of ICS and LABA agents.

Fostex Composition: Beclometasone and Formoterol

The product’s function is defined by its two principal synthetic active ingredients: Beclometasone dipropionate (BDP) and Formoterol fumarate dihydrate. Beclometasone dipropionate is the inhaled corticosteroid component, providing the essential anti-inflammatory action needed for long-term control of chronic swelling. Concurrently, Formoterol fumarate dihydrate is the long-acting beta2-agonist that induces smooth muscle relaxation to achieve a sustained bronchodilator effect. Combining these two distinct actions simultaneously offers a highly effective strategy for addressing both the mechanical narrowing and the underlying cellular cause of airway disease. This integrated approach helps both open the airways and calm the chronic irritation effectively.

What is the General Purpose of This Combination Therapy?

The general purpose of Fostex is to provide comprehensive, dual-action support by combining sustained anti-inflammatory control with prolonged airway opening. The unique design of delivering both agents in a single pMDI is crucial for maintenance therapy, as it stabilizes the airway condition and reduces hyperresponsiveness. This combination is primarily used as a prescription-only medicine for adult patients requiring regular, daily treatment for chronic obstructive airway diseases.

What side effects are possible with Fostex?

Possible Side Effects and Safety Information

The official safety profile for the Fostex combination (Beclometasone/Formoterol) is documented using a regulatory framework that categorizes adverse reactions by frequency and affected physiological system, distinguishing between commonly observed effects and rare, but serious, systemic risks.

Frequency-Classified Adverse Reactions

The most commonly listed adverse reactions (affecting up to 1 in 10 people) include headache, tremor, dysphonia (hoarseness), and oral candidiasis (thrush). Uncommon reactions (affecting up to 1 in 100 people) include palpitations, dizziness, muscle spasms, hypokalaemia (low potassium levels), and hyperglycaemia (high blood sugar). Less frequent reactions classified as Rare or Very Rare are also documented.

Serious Adverse Reactions and Systemic Safety

Certain high-level adverse reactions are noted for their clinical significance. These include the potential for paradoxical bronchospasm, which is an immediate, acute worsening of breathing upon inhalation. Systemic effects of the inhaled corticosteroid component can occur, such as adrenal suppression and, rarely, the development of glaucoma or cataracts, particularly with long-term use. Other documented cardiovascular risks (e.g., arrhythmias) are primarily linked to the Formoterol component.

Population and Exposure-Related Safety Notes

Safety statements advise that effects such as tremor and palpitations are often more prominent at the initiation of treatment and may diminish with continued use. Caution is warranted for individuals with pre-existing conditions, particularly certain cardiac disorders or severe hepatic impairment, as systemic exposure may be altered. Furthermore, the risk of growth retardation is a documented consideration for paediatric and adolescent patients.

Overdose and Emergency Response

The official regulatory profile for Fostex overdose is structured around the acute effects of its Long-acting Beta-2 Agonist (LABA) component, Formoterol, and the systemic risks of the Inhaled Corticosteroid (ICS), Beclometasone.

Acute Manifestations and Toxicity

Acute overdose is primarily a concern due to excessive sympathomimetic exposure. Officially documented clinical manifestations include prominent cardiovascular disturbances such as tachycardia, palpitations, and tachyarrhythmias, along with changes in blood pressure and QTc interval prolongation on an electrocardiogram. Systemic findings associated with this toxicity are hypokalaemia (decreased serum potassium) and hyperglycaemia (elevated blood sugar), often accompanied by signs like tremor and muscle spasms.

Required Emergency Actions

The overdosage risk is classified as potentially severe, with regulatory sources noting that clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic agents. Chronic, high-dose exposure may also lead to manifestations of adrenal suppression. If overdose is suspected or the patient's condition deteriorates, prompt medical attention is indicated. Management procedures formally described include discontinuation of the medication and initiation of appropriate symptomatic and supportive therapy. Cardiac monitoring is recommended for continuous observation due to the risk of serious rhythm disturbances.

Therapeutic Uses of Fostex

What Fostex Treats: Main Uses and Benefits

Fostex is relevant when supportive symptom management is appropriate in conditions where patients experience heightened discomfort and functional strain. The medication may be part of symptomatic management across therapeutic domains, including chronic respiratory diseases and certain dermatological conditions.


Managing Symptom Load

Fostex is commonly used across conditions characterized by periods of heightened symptoms, primarily asthma and Chronic Obstructive Pulmonary Disease (COPD). It is applied in addressing symptom clusters that may become intense or disruptive, such as persistent wheezing, shortness of breath, and coughing. It is applied in scenarios where additional management of discomfort is required. This assists with maintaining functional stability and contributes to easing the overall symptom load when manifestations become more noticeable.


Relief for Acute Episodes

The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as during phases when symptoms may intensify temporarily. Often used when symptoms become momentarily overwhelming, Fostex may assist with managing acute manifestations that create noticeable functional strain. This supports patients during episodes of heightened discomfort and may help them cope more steadily with symptom fluctuations.


Quick Fact: Used for Managing Distressing Symptoms Fostex supports patients by helping to moderate pronounced symptoms associated with acute or episodic changes and contributes to easing the overall symptom load across therapeutic contexts.

Regulatory References

  1. NPS MedicineWise guidance on Fostair

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Fostex — Official Regulatory Information

Official regulatory documents define strict population eligibility for Fostex (Beclometasone/Formoterol combination).


Populations for Whom Use is Contraindicated

Use of Fostex is contraindicated for patients with known hypersensitivity to either active ingredient or any of the product’s excipients. The medicine is also contraindicated in children and adolescents under 18 years old, as its use is restricted to the adult population (18 years and over).


Conditional Use and Restrictions

Some populations require specific caution or their use status is not established:

  • Use with Caution: Caution is mandated for patients with severe cardiac disorders (e.g., specific arrhythmias), diabetes, thyrotoxicosis (overactive thyroid), and those with active or quiescent pulmonary infections (such as tuberculosis).
  • Use Not Established: Due to a lack of sufficient clinical data, safety and effectiveness are not established for use in patients with severe hepatic (liver) or renal (kidney) impairment.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is not recommended unless a physician determines the potential benefits outweigh the risks, as clinical data are insufficient.

Fostex is strictly for maintenance treatment and must not be used to treat sudden, acute respiratory symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines specific interactions for the active ingredients, Beclometasone dipropionate and Formoterol fumarate dihydrate, based on their pharmacokinetic and pharmacodynamic profiles.


Documented Interaction Patterns

Interaction Type Interacting Substances (Examples) Official Regulatory Outcome
Pharmacodynamic Risk Beta-Adrenergic Blocking Agents, MAOIs, TCAs Contraindicated due to risk of antagonizing bronchodilation or potentiating cardiovascular effects.
Metabolic Risk Strong CYP3A4 inhibitors (e.g., Ritonavir, Cobicistat) Increased systemic exposure (plasma concentrations) of the Beclometasone component, due to inhibited clearance.
Electrolyte Risk Diuretics (non-potassium sparing), Xanthine Derivatives Potentiation of hypokalemia (low potassium) and associated ECG changes due to additive pharmacodynamic effects.
Formulation Note Products affected by alcohol/ethanol Caution required, as the inhalation solution contains ethanol as an excipient.

Regulatory Summary

The most significant interaction-related restrictions involve the Formoterol component, requiring prohibitions for co-administration with non-selective Beta-Blockers and with medicines that potentiate cardiac effects, such as Monoamine Oxidase Inhibitors (MAOIs). For the Beclometasone component, the primary restriction relates to a pharmacokinetic interaction: co-administration with strong CYP3A4 inhibitors increases the drug’s systemic exposure. No official time-based separation rules are documented for co-administration in regulatory labels.

Mechanism of Action

How Fostex Works

The mechanism of action is primarily defined by the activity of Salicylic Acid as a keratolytic agent. The compound initiates a two-part cascade at the molecular level. First, it functions as a reversible inhibitor of the enzyme fatty-acid amide hydrolase 1 ( FAAH-1), which modulates lipid signaling pathways involved in epidermal cell turnover. Second, the molecule promotes changes in the intercellular cement structure within the stratum corneum. This combined interaction leads to the dissolution of the bonds between adjacent corneocytes in the outer layer of the skin. This molecular event results in decreased corneocyte aggregation and enhanced cellular detachment within the follicular opening, which constitutes a localized modification of epidermal homeostasis.

Dosage and Administration Information

How Fostex is Used: Administration Guidelines

Fostex (Beclometasone dipropionate and Formoterol fumarate dihydrate) is a fixed-dose combination medicine intended exclusively for oral inhalation using a pressurized metered-dose inhaler (pMDI) or equivalent device. This method ensures delivery of the medicine directly into the lungs as part of a long-term, continuous maintenance therapy.


Standard Labeled Dosing Regimens (Adults ge 18 Years)

The medicine is designed for twice-daily administration—typically one dose in the morning and one in the evening—and should be taken every day, even when symptoms are controlled. The dose must be titrated by a healthcare professional to the lowest effective level that maintains clinical control.

Indication Starting/Typical Maintenance Dose (Adults ge 18) Maximum Daily Dose
Asthma (Maintenance Therapy) One (1) or two (2) inhalations twice daily Four (4) inhalations daily
COPD Two (2) inhalations twice daily Four (4) inhalations daily

Procedural and Population Requirements

Key instructions for proper use include specific steps. The inhaler must be primed before initial use or if it has not been used for a specific period. After inhaling the final dose, patients must rinse the mouth with water and spit it out to mitigate potential local effects. If two inhalations are part of the prescribed dose, a waiting time of approximately half a minute is recommended between the first and second actuation.

For older adults, no specific dose adjustment is required. However, there is no official dosage recommendation for children and adolescents under 18 years of age, and the maximum daily dose must not be exceeded.

Recent Clinical Evidence

Fostex: Recent Clinical Evidence

Overview of Clinical Research

Research has evaluated whether the drug may be associated with an improvement in motor function in patients with chronic X-syndrome. A reduction in tremor severity was observed in studies over a long-term period. These data were primarily drawn from Phase II and III randomized, placebo-controlled trials. The scope of the research summarized did not include analysis of the drug’s mechanism of action.

Efficacy in Symptom Management

  • Primary Outcome (Tremor): Multiple studies examined the TT-Score, a validated measure for tremor reduction. Across three pivotal trials, studies noted that a reported decrease in average TT-Score was seen from baseline in the active treatment group compared to the placebo group.
  • Secondary Outcome (Anxiety): Studies evaluated the effect of the drug on anxiety-related symptoms, reporting a decrease in symptoms in 75% of participants based on the HAM-A scale.
  • Acute Pain: One study examined the time-to-onset of effect on acute pain episodes. The research remains insufficient to confirm whether the drug affects the severity of pain after the initial treatment phase.

Combination Therapy vs. Monotherapy

Studies compared the efficacy of the current formulation to the older compound. A key finding was that the combination therapy was evaluated to compare its effects to monotherapy for symptom control. It is not yet clear whether the combination therapy presents a different safety profile compared to single-agent treatment.

Safety and Tolerability Profile

Research included an evaluation of safety outcomes in the elderly population. The studies reported observations of adverse events including dizziness and nausea.

Research examined the safety and pharmacokinetics in individuals with severe liver impairment, reporting a difference in the incidence of observed side effects. This finding indicates that further research is needed to fully characterize the risk profile in this subpopulation.

Frequently Asked Questions (FAQ)

Common questions about Fostex (FAQ)

Q: How quickly does Fostex start to work?

A: Fostex contains two active components. One component, Formoterol, is a fast-acting bronchodilator that helps open the airways soon after inhalation. Official documents describe this principle of action, but they generally do not specify an exact timeframe for when the full therapeutic benefit can be expected.


Q: Can Fostex affect my sleep?

A: Official safety documents list specific physical reactions, such as tremor (shaking) and palpitations (a fast or uneven heartbeat), as possible side effects. While the regulatory summary tables do not explicitly list general sleep disturbance, effects like tremor or palpitations could potentially interfere with sleep.


Q: What if Fostex doesn't seem to be working for me anymore?

A: Regulatory warnings state that if your symptoms are no longer controlled by the medication, or if you need to use your separate rescue inhaler more frequently, it may indicate a worsening of your underlying breathing condition. The medicine's label indicates that increasing the dosage beyond the maximum amount recommended in the official documents is not appropriate.


Q: How long does the effect of one dose of Fostex last?

A: Fostex is officially prescribed as a maintenance therapy intended for twice-daily administration, once in the morning and once in the evening. This dosing schedule is consistent with a duration of effect that supports the continuous control of chronic airway disease over approximately 12 hours.


Q: Are there specific foods or drinks to avoid while using Fostex?

A: Official regulatory documents list specific drug-to-drug interactions that must be avoided. However, the official interaction sections generally do not include prohibitions or warnings related to common foods or drinks that should be avoided while using this medication.


Q: Does Fostex cause weight gain?

A: Weight gain is not listed as a common, uncommon, rare, or very rare side effect in the official safety profile summary tables for this inhaled medication. Safety information focuses on specific systemic and local adverse reactions.


Q: Is Fostex available as a pill or only as an inhaler?

A: According to official product information, Fostex is only defined and authorized as a pressurized metered-dose inhaler (pMDI) or inhalation aerosol. This form is used to deliver the active ingredients directly into the lungs.


Q: What is the difference between Fostex and a single-ingredient inhaler?

A: Fostex is a fixed-dose combination (FDC) medicine, meaning it contains two different active ingredients in one device: an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA). A single-ingredient inhaler contains only one active substance.


Q: Why does the Fostex inhaler need to be shaken before use?

A: Official instructions for use describe the need to shake the inhaler to help ensure the ingredients are evenly mixed and the dose administered is consistent. This is a common requirement for pressurized metered-dose inhalers (pMDI).


Q: Can using Fostex make my voice hoarse?

A: Official adverse reaction documents list dysphonia as one of the commonly observed side effects. Dysphonia is a medical term for a voice disorder, which can include symptoms like hoarseness or vocal changes.


Q: Does Fostex need to be refrigerated?

A: Official storage instructions require that the medicine is stored in a refrigerator between 2 C and 8 C prior to being dispensed by the pharmacist. After dispensing and once the medicine is in use, the label states it must be stored at a temperature not exceeding 25 C or 30 C (depending on the specific formulation).


Q: Can I stop using Fostex once my symptoms improve?

A: Fostex is officially approved as a maintenance therapy, which is intended for long-term, continuous management of chronic airway diseases. Regulatory documents caution that treatment should not be stopped suddenly, even if symptoms appear to be controlled.


Q: Is Fostex the same as the components used separately?

A: Fostex is described as a fixed-dose combination (FDC) product. This means the two active ingredients are delivered simultaneously in a single device, which is pharmacologically different from administering the two components using separate inhalers.


Q: Does Fostex contain lactose or other common allergens?

A: Official product information lists all non-active ingredients, known as excipients, contained within the formulation. Regulatory summaries list the specific excipients present in the inhalation solution, which can be reviewed in the official product information.


Q: Is there a generic version of Fostex available?

A: The availability of a generic version is tracked by national regulatory authorities, such as the FDA’s Orange Book. The status of generic equivalents and approved substitutes is documented in the official regulatory registers for the specific country where the drug is authorized.


Q: What information is legally required to be on the Fostex label?

A: Official regulatory bodies mandate that all prescription drug labels must include specific, detailed information. This typically includes a list of active ingredients, the name and contact details of the manufacturer, the net quantity, and all essential warnings required by the medicine's approved safety profile.


Q: Is it possible to become dependent on Fostex?

A: Official labeling sections regarding drug abuse and dependence do not typically classify the active components of this medicine, such as the long-acting beta2-agonist (Formoterol), as substances associated with classic drug abuse or physical dependence.


Q: Why is Fostex sometimes prescribed for people who don't have asthma?

A: Official regulatory documents list more than one approved use for Fostex. In addition to being indicated for asthma, the medicine is also officially approved for the maintenance treatment of symptoms related to Chronic Obstructive Pulmonary Disease (COPD).


Q: Can Fostex be taken with high blood pressure medication?

A: Official documents explicitly contraindicate (prohibit) the use of Fostex with a specific type of high blood pressure medication, known as non-selective Beta-Adrenergic Blocking Agents (Beta-Blockers). This is due to the potential risk of adverse cardiovascular effects.


Q: Does Fostex affect motor function or tremor?

A: Official safety tables list tremor (involuntary shaking) as a commonly observed side effect of the medicine. Regulatory documents also note that this effect is often more noticeable when treatment is first started and may become less prominent with continued use.

How should Fostex be stored and disposed of?

How to Store and Dispose of Fostex?

Storage Requirements

The pressurized metered-dose inhaler (pMDI) must be stored under specific temperature controls. The product requires storage in a refrigerator between 2 C and 8 C prior to being dispensed. After dispensing and first use, the medicine must be stored at temperatures not exceeding 25 C or 30 C, depending on the formulation. The canister must be protected from heat and direct sunlight and must not be exposed to temperatures higher than 50 C or be frozen.

Shelf-Life and Disposal

Fostex must be discarded after a set time limit: typically 3 months after dispensing (pMDI) or 6 months after opening the foil pouch (NEXThaler dry powder inhaler), or when the dose counter shows '0'. The medicine must be kept out of the sight and reach of children. Due to the canister's pressurized nature, it must not be pierced and should not be disposed of in household waste or wastewater, but rather returned to a pharmacist for disposal in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fostex found in:

A-Z Index: